ArticleFrontiers in immunology2026
Increased number of crosslinking sites for factor XIII counteracts the mechanical and lytic destabilization of fibrin caused by citrullination of fibrinogen.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: In thrombi, fibrin formation is accompanied by neutrophil activation, which leads to the release of neutrophil extracellular traps (NETs). Citrullination is a post-translational modification of arginine catalyzed by peptidylarginine deiminases, which are released during NET formation and modify extracellular proteins. Citrullinated fibrin has been detected within thrombi, but its impact on clot stabilization by activated Factor XIII (FXIIIa) has not been investigated. Objective: To characterize the effect of FXIIIa on the mechanical strength and lytic susceptibility of citrullinated fibrin. Methods: FXIII cross-linking sites in fibrin were identified by mass spectrometry. Fibrinolysis was investigated by turbidimetry and viscoelastometry in clots containing plasminogen and tissue plasminogen activator (tPA). Mechanical and viscoelastic parameters of the same clots were determined by oscillatory rheometry and viscoelastometry. Results: Non-crosslinked fibrin formed from citrullinated fibrinogen showed lower stability in the applied biomechanical and fibrinolytic assays. However, citrullination increased the number of heterochain crosslinks formed by FXIIIa from 27 to 36, and that of homochain crosslinks from 29 to 30. In line with this finding, the antifibrinolytic effect of FXIII crosslinking was consistently more pronounced in citrullinated fibrin. While FXIIIa increased the maximal clot firmness of native fibrin by 10% in the viscoelastometric assay, this FXIII-related rise in mechanical strength was 38% in citrullinated fibrin. Similarly, in the rheometric assays, the FXIII-associated increment in the critical shear stress required to disassemble the clot was higher in citrullinated fibrin than in the native one. Conclusion: FXIIIa is essential to counteract the weakening effects of citrullination in fibrin clots.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.